| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d53094985a54e1cafd22f23d76be4007 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
| filingDate |
2004-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4557737c7fece6903fa50b25b7200213
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69efbb2590d4415ac75354b8924c3278 |
| publicationDate |
2004-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2512090-A1 |
| titleOfInvention |
Cytokine inhibition of eosinophils |
| abstract |
A composition and method to alter eosinophil function and recruitment. An allergen-induced chemokine with inhibitory activity on eosinophils, monokine induced by interferon y (MIG) and/or an IFN-y-inducible protein of 10 kDa (IP-10), is administered in a pharmaceutically acceptable dose and formulation. The composition is used for prophylaxis and therapy of diseases in which eosinophilia occurs and may be administered, for example, to allergic patients and asthmatic patients. |
| priorityDate |
2003-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |